Asset 1

Collaborate with the Pioneers
Behind the PDL-1 and HER2
Companion Diagnostic Assays

Discovery is renowned for having the largest commercial biorepository, providing access to a vast collection of high-quality, characterized biospecimens to accelerate the development and validation of diagnostic and companion diagnostic assays. Our biospecimen solutions are integrated with advanced laboratory facilities and state-of-the-art technologies to enable comprehensive biomarker analysis and validation, facilitating the translation of discoveries into clinically relevant diagnostic tests.

Leverage our extensive technology, expertise, and infrastructure to accelerate the development and validation of your innovative diagnostic solutions.

Expertise & Specialization

Regulatory Compliance

Quality Assurance & Control

Timeliness & Flexibility

Communication & Collaboration

Data Security, Personal Data Protection & Confidentiality

Infrastructure & Equipment

Featured Biospecimens

Discovery has the world’s largest commercial biorepository and offers a full spectrum of biospecimens to meet the evolving needs of growing pharmaceutical and biotech companies:

Dissociated Tumor Cells (DTCs)

FFPE and Matched Sets


The Data You Need at Faster Speed.

Discovery’s biomarker services are designed and optimized to offer flexibility and generate high quality data with less samples. We deliver faster turnaround times by simultaneously testing samples using our integrated genomic, proteomic and cell service workflows. 

Discovery’s experts use the latest technologies to help you understand biomarker expression across disease indications and routinely support later stage research and clinical trials by rapidly developing and validating robust assays.

Discovery, Targeted and Quantitative Proteomics

Reliable and customizable proteomic services – from multiplex immunoassays such as Olink to mass spectrometry – enabling improved understanding of real-time human biology.

Proprietary Low-Input Comprehensive Genomic Profiling Pipeline

High-throughput RNA-Seq, WES, targeted and pan-caner sequencing workflows optimized in GCLP-compliant service laboratory for the most challenging sample types such as FFPE and core needle biopsies.

Understand the Phenotypic and Functional Biomarkers with Cutting-Edge Flow Cytometry Technology

Discovery’s clinical flow cytometry laboratory delivers high-resolution multiparametric flow cytometry data for rapid, high-throughput screening of compounds assessing their effects on cellular targets, efficacy in disease models, and identification of potential therapeutic candidates

Custom Molecular Pathology Assay Development

Pathologist-driven, GCLP-compliant procedures for developing and validating AI driven digital image analysis and custom IHC/mIF assays in CAP-accredited and CLIA-certified GCLP compliant laboratories.

Case Studies

Establishing HER2 as a Companion Diagnostic Biomarker for the Treatment of Breast & Gastric Cancers

Discovery has been instrumental in helping determine HER2 assay design, evaluation, scoring, and clinical utility for use in breast, esophageal and gastric cancers.Download

Development of the Prototype IHC CDx Assay that Advanced Development of Pembrolizumab

Discovery developed an assay with dynamic range, high precision and reproducibility, laying the foundation for the successful 22C3 PD-L1 companion diagnostic assay widely utilized today.Download

Retrospective RNA-Seq of DD-LPS Phase II-III Clinical Trial Patients Reveals a Potential Biomarker of Selinexor Response

Discovery conducted a retrospective, exploratory RNA sequencing study in collaboration with Karyopharm Therapeutics using FFPE dedifferentiated liposarcoma (DD-LPS) tumor samples revealing a potential predictive biomarker.Download

Identify Molecular Drivers of Cancer via Comprehensive Sequencing with Matched Germline and Clinical Data

Contributing to the ORIEN Avatar program, Discovery Genomics has conducted high yield, high quality dual RNA/DNA isolation from FFPE specimens, WES and RNA-Seq services on more than 30,000 tumor and non-tumor samples. Watch Webinar

Trust an Experienced Industry Partner to Win Government Projects Together.

Discovery has supported major government-funded projects, including NIH’s Gabriella Miller Kids First and All of Us programs. We have tested over 50,000 NGS samples for ongoing government collaborations.

With our extensive experience in aligning government priorities with cutting-edge technologies and resources, Discovery is dedicated to assisting our biopharma partners in maximizing their chances of winning government-funded projects.

Contact Us Today

Quick Links


Development and Clinical
Trial Solutions